Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
We have shown that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (Lir) inhibits development of early atherosclerosis in vivo by modulating immune cell function. We hypothesized that Lir could attenuate pre-established disease by modulating monocyte or macrophage phenotype to induce atheroprotective responses. Human atherosclerotic plaques obtained postendarterectomy and human peripheral blood macrophages were treated ex vivo with Lir. In parallel, apolipoprotein E–deficient (ApoE−/−) mice received a high-fat, high-cholesterol diet to induce atherosclerosis for 8 weeks, after which ApoE−/− mice received 300 μg/kg of Lir daily or vehicle control for a further 4 weeks to investigate the attenuation of atherosclerosis. Lir inhibited proinflammatory monocyte chemoattractant protein-1 secretion from human endarterectomy samples and monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin (IL)-1β secretion from human macrophages after ex vivo treatment. An increase in CD206 mRNA and IL-10 secretion was also detected, which implies resolution of inflammation. Importantly, Lir significantly attenuated pre-established atherosclerosis in ApoE−/− mice in the whole aorta and aortic root. Proteomic analysis of ApoE−/− bone marrow cells showed that Lir upregulated the proinflammatory cathepsin protein family, which was abolished in differentiated macrophages. In addition, flow cytometry analysis of bone marrow cells induced a shift toward reduced proinflammatory and increased anti-inflammatory macrophages. We concluded that Lir attenuates pre-established atherosclerosis in vivo by altering proinflammatory mediators. This is the first study to describe a mechanism through which Lir attenuates atherosclerosis by increasing bone marrow proinflammatory protein expression, which is lost in differentiated bone marrow–derived macrophages. This study contributes to our understanding of the anti-inflammatory and cardioprotective role of GLP-1RAs. SIGNIFICANCE STATEMENT It is critical to understand the mechanisms through which liraglutide (Lir) mediates a cardioprotective effect as many type 2 diabetic medications increase the risk of myocardial infarction and stroke. We have identified that Lir reduces proinflammatory immune cell populations and mediators from plaque-burdened murine aortas in vivo and augments proresolving bone marrow–derived macrophages in attenuation of atherosclerotic disease, which provides further insight into the atheroprotective effect of Lir.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
The fate and lifespan of human monocyte subsets in steady state and systemic inflammation
Patel, A. A., Zhang, Y., Fullerton, J. N., Boelen, L., Rongvaux, A., Maini, A. A., Bigley, V., Flavell, R. A., Gilroy, D. W., Asquith, B., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170355 · Cited by 946 · cited 2×
“The monocyte-derived macrophage cells within atherosclerotic plaques are thought to originate from bone marrow cells as opposed to recruitment of new circulating monocytes (Patel et al., 2017).”
BackgroundMonocyte-macrophages and T cells in atherosclerosis
Tabas, I., & Lichtman, A. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.008 · Cited by 646 · cited 1×
“In atherosclerotic disease progression, monocytes are recruited to the developing lesion and differentiate into macrophages, which sustain the inflammatory response and drive disease progression (Tabas and Lichtman, 2017).”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 9×
“Indeed, increased circulating MCP-1 levels are related to increased risk of CVD and CVD mortality in patients with coronary artery disease (Ding et al., 2015).”
BackgroundInfluentialNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · cited 9×
“Indeed, increased circulating MCP-1 levels are related to increased risk of CVD and CVD mortality in patients with coronary artery disease (Ding et al., 2015).”
BackgroundInfluentialHogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Vinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
Feig, J. E., Vengrenyuk, Y., Reiser, V., Wu, C., Statnikov, A., Aliferis, C. F., Garabedian, M. J., Fisher, E. A., & Puig, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039790 · Cited by 118 · cited 1×
“Indeed, M2 macrophages have been identified in numerous murine atherosclerosis regression models (Feig et al., 2012).”
Background
Research works printed but not linked: 20
- Bisgaard, 2016, Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr−/− mice, PLoS One, 11, e0168396, 10.1371/journal.pone.0168396 · DOI · Paper page
- Bornfeldt, 2011, Insulin resistance, hyperglycemia, and atherosclerosis, Cell Metab, 14, 575, 10.1016/j.cmet.2011.07.015 · DOI · Paper page
- Brennan, 2018, Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease, J Am Soc Nephrol, 29, 1437, 10.1681/ASN.2017101112 · DOI
- Bruen, 2017, Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis, Cardiovasc Diabetol, 16, 143, 10.1186/s12933-017-0626-3 · DOI · Paper page
- de Gaetano, 2015, Conjugated linoleic acid induces an atheroprotective macrophage MΦ2 phenotype and limits foam cell formation, J Inflamm (Lond), 12, 15, 10.1186/s12950-015-0060-9 · DOI
- de Gaetano, 2016, M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis, Front Immunol, 7, 275, 10.3389/fimmu.2016.00275 · DOI · Paper page
- Ding, 2015, Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease, PLoS One, 10, e0120633, 10.1371/journal.pone.0120633 · doi:10.1371/journal.pone.0120633
- Erbel, 2014, A human ex vivo atherosclerotic plaque model to study lesion biology, J Vis Exp, 87, 1
- Fadini, 2013, An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy, Diabetologia, 56, 1856, 10.1007/s00125-013-2918-9 · DOI
- Fujisaka, 2009, Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice, Diabetes, 58, 2574, 10.2337/db08-1475 · DOI · Paper page
- Gaspari, 2011, A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model, Diab Vasc Dis Res, 8, 117, 10.1177/1479164111404257 · DOI · Paper page
- Gerhard, 1999, Homocysteine and atherosclerosis, Curr Opin Lipidol, 10, 417, 10.1097/00041433-199910000-00006 · DOI · Paper page
- Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 · DOI · Paper page
- McCarthy, 2013, IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis, FASEB J, 27, 499, 10.1096/fj.12-215442 · DOI
- Nikiforov, 2017, Proinflammatory monocyte polarization in type 2 diabetes mellitus and coronary heart disease, Vessel Plus, 1, 192
- O’Reilly, 2016, High-density lipoprotein proteomic composition, and not efflux capacity, reflects differential modulation of reverse cholesterol transport by saturated and monounsaturated fat diets, Circulation, 133, 1838, 10.1161/CIRCULATIONAHA.115.020278 · DOI
- Rahman, 2017, Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression, J Clin Invest, 127, 2904, 10.1172/JCI75005 · DOI · Paper page
- Ross, 1993, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature, 362, 801, 10.1038/362801a0 · DOI · Paper page
- Ye, 2016, Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance, Life Sci, 166, 82, 10.1016/j.lfs.2016.09.025 · DOI
- Zhao, 2016, The function of cathepsins B, D, and X in atherosclerosis, Am J Cardiovasc Dis, 6, 163
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“, by lixisenatide [146], liraglutide [147], and dulaglutide [141]).”
BackgroundMarx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
Metadata
- Authors
- Bruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., & Belton, O.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 370
- Issue
- 3
- Pages
- 447-458
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2953693496
- Cited by
- 52
- References
- 11
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. https://app.cochat.ai/papers/10.1124/jpet.119.258343
- The paper
- Bruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., & Belton, O. (2019). Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.119.258343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.